307 related articles for article (PubMed ID: 11432342)
21. Detection of minimal residual disease in acute leukemia.
van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
[TBL] [Abstract][Full Text] [Related]
22. Monitoring minimal residual disease using chromosomal translocations in childhood ALL.
Cazzaniga G; Rossi V; Biondi A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):21-35. PubMed ID: 11987914
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
24. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.
Agrawal S; Unterberg M; Koschmieder S; zur Stadt U; Brunnberg U; Verbeek W; Büchner T; Berdel WE; Serve H; Müller-Tidow C
Cancer Res; 2007 Feb; 67(3):1370-7. PubMed ID: 17283175
[TBL] [Abstract][Full Text] [Related]
25. The detection and significance of minimal residual disease in acute and chronic leukemia.
Chung NG; Buxhofer-Ausch V; Radich JP
Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
[TBL] [Abstract][Full Text] [Related]
26. Detection and monitoring of minimal residual disease by quantitative real-time PCR.
Schüler F; Dölken G
Clin Chim Acta; 2006 Jan; 363(1-2):147-56. PubMed ID: 16154122
[TBL] [Abstract][Full Text] [Related]
27. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
28. The significance of detecting WT1 expression in childhood acute leukemias.
Hu SY; Gu WY; Chen ZX; Wang XL; Cen JN; He HL; Chai YH; Chen CS
Pediatr Hematol Oncol; 2010 Nov; 27(8):581-91. PubMed ID: 20863155
[TBL] [Abstract][Full Text] [Related]
29. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan.
Imashuku S; Terui K; Matsuyama T; Asami K; Tsuchiya S; Ishii E; Kawa K; Kosaka Y; Eguchi H; Tsuchida M; Ikuta K; Kato S; Koizumi S; Okamura J; Morimoto A; Hibi S; Hamaoka K;
Bone Marrow Transplant; 2003 Jun; 31(12):1127-35. PubMed ID: 12796792
[TBL] [Abstract][Full Text] [Related]
30. Monitoring of minimal residual disease using WT1 assay for patients with chronic myeloid leukemia who undergo allogeneic stem cell transplantation.
Tamaki H; Ogawa H
Bone Marrow Transplant; 2004 Oct; 34(7):653-4. PubMed ID: 15258561
[No Abstract] [Full Text] [Related]
31. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
[TBL] [Abstract][Full Text] [Related]
32. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
33. Application of the polymerase chain reaction for detection of minimal residual disease of hematologic malignancies.
Roth MS; Terry VH
Henry Ford Hosp Med J; 1991; 39(2):112-6. PubMed ID: 1890004
[TBL] [Abstract][Full Text] [Related]
34. [The clinical significance of minimal residual disease of acute leukemia with t(4;11) (q21;q23)].
Okamura T; Park YD; Inoue M; Yasui M; Ueno M; Endo C; Yagi K; Kawa K
Rinsho Ketsueki; 1996 Nov; 37(11):1318-21. PubMed ID: 8960669
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
36. Follow-up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience.
Magyarosy E; Varga N; Timár J; Rásó E
Pediatr Hematol Oncol; 2003; 20(1):65-74. PubMed ID: 12687755
[TBL] [Abstract][Full Text] [Related]
37. Molecular biology strategies to detect residual disease.
Garcés-Eisele J
Hematology; 2012 Apr; 17 Suppl 1():S66-8. PubMed ID: 22507783
[TBL] [Abstract][Full Text] [Related]
38. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]